Patrick Zweidler-McKay
Overview
Explore the profile of Patrick Zweidler-McKay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schore R, Angiolillo A, Kairalla J, Devidas M, Rabin K, Zweidler-McKay P, et al.
Leukemia
. 2023 May;
37(6):1406.
PMID: 37157018
No abstract available.
2.
Schore R, Angiolillo A, Kairalla J, Devidas M, Rabin K, Zweidler-McKay P, et al.
Leukemia
. 2023 Mar;
37(6):1375-1378.
PMID: 36966262
No abstract available.
3.
Gupta S, Dai Y, Chen Z, Winestone L, Teachey D, Bona K, et al.
Lancet Haematol
. 2023 Feb;
10(2):e129-e141.
PMID: 36725118
Background: Previous studies have identified racial and ethnic disparities in childhood acute lymphocytic leukaemia survival. We aimed to establish whether disparities persist in contemporaneous cohorts and, if present, are attributable...
4.
Teachey D, Devidas M, Wood B, Chen Z, Hayashi R, Hermiston M, et al.
J Clin Oncol
. 2022 Mar;
40(19):2106-2118.
PMID: 35271306
Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III...
5.
Rau R, Dai Y, Devidas M, Rabin K, Zweidler-McKay P, Angiolillo A, et al.
Pediatr Blood Cancer
. 2021 Feb;
68(4):e28929.
PMID: 33559396
The 5-year disease-free survival (DFS) of National Cancer Institute (NCI) high-risk (HR) B-lymphoblastic leukemia (B-ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation...
6.
Angiolillo A, Schore R, Kairalla J, Devidas M, Rabin K, Zweidler-McKay P, et al.
J Clin Oncol
. 2021 Jan;
39(13):1437-1447.
PMID: 33411585
Purpose: AALL0932 evaluated two randomized maintenance interventions to optimize disease-free survival (DFS) while reducing the burden of therapy in children with newly diagnosed NCI standard-risk (SR) B-acute lymphoblastic leukemia (B-ALL)....
7.
Esbenshade A, Pierson C, Thompson A, Reed D, Gupta A, Levy A, et al.
Pediatr Blood Cancer
. 2017 Dec;
65(3).
PMID: 29193588
Background: Mentorship of junior faculty is an integral component of career development. The Children's Oncology Group (COG) Young Investigator (YI) Committee designed a mentorship program in 2004 whose purpose was...
8.
Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S, Gopalakrishnan V
Oncotarget
. 2017 Nov;
8(49):86657-86670.
PMID: 29156825
Selectins and their ligands have been implicated in tumor growth and progression in carcinomas, but their role in neuroblastoma has not been systematically examined. In the current study we evaluated...
9.
Maher O, Silva J, Wu J, Liu D, Cooper L, Tarek N, et al.
Pediatr Transplant
. 2017 Feb;
21(3).
PMID: 28160352
We conducted a retrospective analysis of outcomes for children and young adults with sAML/sMDS who underwent HSCT at our institution. Thirty-two patients (median age 20 years) with sAML (n=24) and...
10.
Jain N, Roberts K, Jabbour E, Patel K, Eterovic A, Chen K, et al.
Blood
. 2016 Dec;
129(5):572-581.
PMID: 27919910
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph-like ALL in adults. Patients...